These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2148009)

  • 1. [Acute rhabdomyolysis during treatment with ciprofibrate].
    Delangre T; Vernier L; Moore N; Mihout B
    Presse Med; 1990 Nov; 19(39):1811-2. PubMed ID: 2148009
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rhabdomyolysis and unexplained malaise. Role of combination of ciprofibrate and norfloxacin].
    Blain H; Klein M; Weryha G; Tréchot P; Hanesse B; Leclère J
    Rev Med Interne; 1996; 17(10):859-60. PubMed ID: 8976986
    [No Abstract]   [Full Text] [Related]  

  • 3. Acute renal failure due to rhabdomyolysis in presence of concurrent ciprofibrate and ibuprofen treatment.
    Ramachandran S; Giles PD; Hartland A
    BMJ; 1997 May; 314(7094):1593. PubMed ID: 9186171
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe rhabdomyolysis during a hypersensitivity reaction to abacavir in a patient treated with ciprofibrate.
    Fontaine C; Guiard-Schmid JB; Slama L; Essid A; Lukiana T; Rondeau E; Pialoux G
    AIDS; 2005 Nov; 19(16):1927-8. PubMed ID: 16227807
    [No Abstract]   [Full Text] [Related]  

  • 5. [Ciprofibrate-induced acute cholestatic hepatitis].
    Pflumio F; Andrès E; Ubrich M; Geisler F; Imbs JL; Di Liberatore M
    Ann Endocrinol (Paris); 2003 Jun; 64(3):232-3. PubMed ID: 12910067
    [No Abstract]   [Full Text] [Related]  

  • 6. [Acute severe fibrosing hepatitis associated with ciprofibrate treatment].
    Dumortier J; Slim R; Chevallier M; Boillot O; Thaunat JL; Vaillant E; Vial T; Bellemin B; Paliard P; Scoazec JY
    Gastroenterol Clin Biol; 1999 Dec; 23(12):1399-400. PubMed ID: 10642628
    [No Abstract]   [Full Text] [Related]  

  • 7. Ciprofibrate and lipid profile.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1994 Oct; 344(8927):955. PubMed ID: 7934365
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cytolytic hepatic damage caused by ciprofibrate].
    Perault MC; Fievre JL; Dejean C; Martin A; Vandel B
    Gastroenterol Clin Biol; 1992; 16(6-7):609. PubMed ID: 1526424
    [No Abstract]   [Full Text] [Related]  

  • 9. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP; Jagroon IA
    Metabolism; 2001 Nov; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract]   [Full Text] [Related]  

  • 10. [Does hypothyroidism predispose muscular toxicity of fibrates?].
    Tregouet B
    Rev Med Interne; 1991; 12(2):159. PubMed ID: 1853004
    [No Abstract]   [Full Text] [Related]  

  • 11. Fibrates and renal function.
    Gajdos M; Dzúrik R
    Clin Nephrol; 2003 Jul; 60(1):65-6. PubMed ID: 12872864
    [No Abstract]   [Full Text] [Related]  

  • 12. Drugs recently released in Belgium. Mefloquine--ciprofibrate.
    Harvengt C
    Acta Clin Belg; 1991; 46(2):117-9. PubMed ID: 1649529
    [No Abstract]   [Full Text] [Related]  

  • 13. [Myositis, hypothyroidism and fibrates].
    Wechsler B; Doumith R; Weil M
    Rev Med Interne; 1991; 12(6):475. PubMed ID: 1792441
    [No Abstract]   [Full Text] [Related]  

  • 14. [Does hypothyroidism potentialize muscular toxicity of fibrates?].
    Harlé JR; Toussirot E; Disdier P; Drancourt M; Weiller PJ
    Rev Med Interne; 1990; 11(4):336. PubMed ID: 2096444
    [No Abstract]   [Full Text] [Related]  

  • 15. [Rhabdomyolysis under treatment by ciprofibrate in the nephrotic syndrome].
    Baglin A; Lasserre N; Prinseau J; Lebas M
    Therapie; 1987; 42(2):247-8. PubMed ID: 3617003
    [No Abstract]   [Full Text] [Related]  

  • 16. Fibrate monotherapy and profound hypoalphalipoproteinaemia.
    Olukoga AO; Crowley VE; Stewart MF; Weinkove O
    Postgrad Med J; 1996 Mar; 72(845):189. PubMed ID: 8731722
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy.
    Yildiz A; Gucuk E; Cay S
    Acta Cardiol; 2008 Aug; 63(4):515-7. PubMed ID: 18795591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhabdomyolysis and lipid-lowering drugs.
    Tenenbaum A; Fisman EZ; Motro M
    JAMA; 2005 Mar; 293(12):1448; author reply 1448-9. PubMed ID: 15784863
    [No Abstract]   [Full Text] [Related]  

  • 19. Fibrate treatment can increase serum creatinine levels.
    Tsimihodimos V; Kakafika A; Elisaf M
    Nephrol Dial Transplant; 2001 Jun; 16(6):1301. PubMed ID: 11390746
    [No Abstract]   [Full Text] [Related]  

  • 20. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.